Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01130519 |
|---|---|
| Brief Title: | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer |
| First Submitted : | May 25, 2010 |
| First Submitted that Met QC Criteria : | May 25, 2010 |
| First Posted : | May 26, 2010 (Estimate) |
| Results First Submitted : | April 12, 2023 |
| Results First Submitted that Met QC Criteria : | July 17, 2023 |
| Results First Posted : | August 1, 2023 |
| Last Update Submitted that Met QC Criteria : | January 5, 2024 |
| Last Update Posted : | February 1, 2024 |